Novel drug delivery systems for glaucoma

dc.contributor.authorLavik, Erin
dc.contributor.authorKuehn, M H
dc.contributor.authorKwon, Y H
dc.date.accessioned2021-03-19T17:46:53Z
dc.date.available2021-03-19T17:46:53Z
dc.date.issued2011-04-08
dc.description.abstractReduction of intraocular pressure (IOP) by pharmaceutical or surgical means has long been the standard treatment for glaucoma. A number of excellent drugs are available that are effective in reducing IOP. These drugs are typically applied as eye drops. However, patient adherence can be poor, thus reducing the clinical efficacy of the drugs. Several novel delivery systems designed to address the issue of adherence and to ensure consistent reduction of IOP are currently under development. These delivery systems include contact lenses-releasing glaucoma medications, injectables such as biodegradable micro- and nanoparticles, and surgically implanted systems. These new technologies are aimed at increasing clinical efficacy by offering multiple delivery options and are capable of managing IOP for several months. There is also a desire to have complementary neuroprotective approaches for those who continue to show progression, despite IOP reduction. Many potential neuroprotective agents are not suitable for traditional oral or drop formulations. Their potential is dependent on developing suitable delivery systems that can provide the drugs in a sustained, local manner to the retina and optic nerve. Drug delivery systems have the potential to improve patient adherence, reduce side effects, increase efficacy, and ultimately, preserve sight for glaucoma patients. In this review, we discuss benefits and limitations of the current systems of delivery and application, as well as those on the horizon.en_US
dc.description.sponsorshipAll three authors were supported by the Wallace H Coulter Foundation. In addition, EL was supported by a NIH grant DP2OD007338. MK was supported by a NIH grant EY017142. YHK was supported by the Clifford M & Ruth M Altermatt Professorship, Marlene S & Leonard A Hadley Glaucoma Research Fund, and Research to Prevent Blindness.en_US
dc.description.urihttps://www.nature.com/articles/eye201182en_US
dc.format.extent9 pagesen_US
dc.genrejournal articlesen_US
dc.identifierdoi:10.13016/m2mh1t-agwg
dc.identifier.citationLavik, E., Kuehn, M. & Kwon, Y. Novel drug delivery systems for glaucoma. Eye 25, 578–586 (2011). https://doi.org/10.1038/eye.2011.82en_US
dc.identifier.urihttps://doi.org/10.1038/eye.2011.82
dc.identifier.urihttp://hdl.handle.net/11603/21198
dc.language.isoen_USen_US
dc.publisherSpringer Natureen_US
dc.relation.isAvailableAtThe University of Maryland, Baltimore County (UMBC)
dc.relation.ispartofUMBC Chemical, Biochemical & Environmental Engineering Department Collection
dc.rightsThis item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
dc.subjectnanoparticleen_US
dc.subjectPLGAen_US
dc.subjectdrug deliveryen_US
dc.subjectclinical trialsen_US
dc.subjectglaucomaen_US
dc.titleNovel drug delivery systems for glaucomaen_US
dc.typeTexten_US

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.56 KB
Format:
Item-specific license agreed upon to submission
Description: